The mRNA RSV vaccine candidate by Moderna consists of an mRNA sequence encoding for a stabilized prefusion F glycoprotein. The technology follows a similar technology as the SARS-CoV-2 mRNA vaccines, by encapsulating this mRNA inside of a lipid nanoparticle (LNP) to deliver the instructions (mRNA) and then allow our bodies to produce the protein desired (F protein).
You can learn more about their clinical trial here: [ Ссылка ]
